Swallowed fluticasone

PreclinicalSmall molecule

Swallowed fluticasone is one of 43 small molecule programs targeting Eosinophilic Esophagitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eosinophilic EsophagitisActive, not recruiting

Eosinophilic EsophagitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

66 competitors in Eosinophilic Esophagitis

#DrugCompanyPhaseTrials

Pulmicort

SSalix

Approved

12 2

Flovent

GSK

Approved

2 3

Prevacid

Cinqair

2 5

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

10 6

Tezspire

AstraZeneca

Phase 3

1 7

Fasenra

AstraZeneca

Phase 3

1 8

Xolair

Roche

Phase 2

2 9

Lialda

Takeda

Phase 2

1 10

Asmanex

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Eosinophilic Esophagitis1 trial

Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis

Completed·WWalter Reed Army Medical Center·N/A·NCT00895817·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Swallowed fluticasone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Swallowed fluticasone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Swallowed fluticasone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Walter Reed Army Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWalter Reed Army Medical Center

Swallowed fluticasone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Eosinophilic Esophagitis1 trial

References

Drug Info

Quick Facts

Related News